Cue Biopharma (CUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cue Biopharma (CUE) has a cash flow conversion efficiency ratio of -0.681x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.02 Million) by net assets ($13.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CUE market cap for the company's overall valuation and market capitalisation.
Cue Biopharma - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Cue Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cue Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cue Biopharma ranked by their cash flow conversion efficiency. See Cue Biopharma debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Syntara Ltd
AU:SNT
|
-0.694x |
|
Perusahaan Sadur Timah Malaysia Perstima Bhd
KLSE:5436
|
0.069x |
|
KLX Energy Services Holdings Inc
NASDAQ:KLXE
|
-0.224x |
|
Worth Peripherals Limited
NSE:WORTH
|
0.067x |
|
Camellia Metal Co Ltd
TWO:2064
|
0.107x |
|
Salee Industry Public Company Limited
BK:SALEE
|
0.023x |
|
Apollo Power Ltd
TA:APLP
|
-0.074x |
|
KPS Consortium Bhd
KLSE:9121
|
0.004x |
Annual Cash Flow Conversion Efficiency for Cue Biopharma (2015–2024)
The table below shows the annual cash flow conversion efficiency of Cue Biopharma from 2015 to 2024. View Cue Biopharma stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $17.50 Million | $-36.33 Million | -2.076x | -92.66% |
| 2023-12-31 | $37.09 Million | $-39.96 Million | -1.078x | -69.30% |
| 2022-12-31 | $65.68 Million | $-41.81 Million | -0.636x | -7.33% |
| 2021-12-31 | $65.49 Million | $-38.84 Million | -0.593x | -44.01% |
| 2020-12-31 | $78.91 Million | $-32.49 Million | -0.412x | +27.02% |
| 2019-12-31 | $54.58 Million | $-30.80 Million | -0.564x | +27.43% |
| 2018-12-31 | $33.97 Million | $-26.41 Million | -0.777x | -292.87% |
| 2017-12-31 | $61.61 Million | $-12.19 Million | -0.198x | +49.69% |
| 2016-12-31 | $15.17 Million | $-5.97 Million | -0.393x | -64.64% |
| 2015-12-31 | $6.94 Million | $-1.66 Million | -0.239x | -- |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more